Cardiomech Raises $13M In Heavily Oversubscribed Round For Its Transcatheter Mitral Chordal Repair Technology

Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced it has closed on $13M in fresh capital ($42M to-date). CardioMech received strong financial support from existing and new investors, including a non-disclosed strategic investor.